Biotech & Pharma

QurAlis' ALS drug sees early positive signal, but questions remain

25 sec read41 views0 listens

QurAlis reported early positive signals for their ALS drug in Phase 1/2 trial based on biomarker data, though uncertainties persist about its efficacy and safety. This development is significant as it offers a potential new treatment avenue for ALS patients. Content creators should highlight both the promising outcomes and the need for further research when covering this story.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

CybersecurityMar 2926 sec read

Hospital awarded global AI prize for novel Alzheimer's Disease research platform

Dr. Kuan-lin Huang and his team at Mount Sinai Hospital won the $1 million Alzheimer’s Insights AI Prize for developing Biomni-AD, an advanced AI platform that accelerates scientific insights from complex biomedical data. This innovation is crucial a...

Ali Nemati

AI & Machine LearningMar 2530 sec read

USPTO Has a Free Patent API - Search 8M+ Patents (No Key Required)

This article provides a guide on how to programmatically search patents using Python and APIs, offering various use cases such as identifying new technologies, researching company R&D activity, and investment analysis. It includes sample code sni...

Ali Nemati

AI & Machine LearningMar 1923 sec read

Open Biomedical Knowledge Graphs at Scale: Construction, Federation, and AI Agent Access with Samyama Graph Database

Researchers have created three large-scale open-source biomedical knowledge graphs using Samyama graph database, enabling efficient data integration from various sources for better analysis and AI agent access. This development significantly enhances...

Ali Nemati